Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma

Abstract

The results of this study show that an all-oral regimen of tegafur and leucovorin can obtain biochemical modulation, with a significant response rate, in patients with advanced colorectal carcinoma. Randomized trials are needed to assess the possible advantage of this regimen over intravenous schedules.

Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer

“…This combination attempts to simulate the continuous infusion of 5-FU and LV, with the advantage of an ambulant oral treatment. This scheme demonstrated a response rate comparable to that of the continuous infusion of 5-FU in advanced colorectal cancer (38.5%, 95% confi dence interval, 23.2-53.6%) [9], with an acceptable degree of toxicity. Afterwards, we performed a phase III study in metastatic colorectal cancer with a combination of FT and LV, showing that it has an activity equivalent to that of the Mayo schedule [10].…”

Cisplatin-5-Fluorouracil Therapy with Remarkable Effect and 5-Year Survival for Paraaortic Lymph Node Metastases of Rectal Carcinoma in Females: A Case Report

“…As for colorectal carcinoma, LV-5FU therapy is commonly used in Western countries (8)(9)(10)(11)(12). Moreover, several authors have reported that there are no advantages with CDDP-5FU therapy for colorectal carcinoma (19)(20)(21).…”

“…In conclusion, we experienced a valuable case where CDDP-5FU was very effective for paraaortic lymph node metastases of rectal cancer in a female. Although there are many reports on the efficacy of LV-5FU therapy for colorectal cancer in Western countries (8)(9)(10)(11)(12), we think that CDDP-5FU (UFT) therapy may be useful for the treatment of colorectal cancer by an appropriate protocol and the prevention of side effects such as vomiting and renal disorders.…”

“…Cisplatin (CDDP)-5FU therapy is one of those based on the concept of biochemical modulation and is widely used for gastric and esophageal carcinoma (1-7). In contrast, as for colorectal carcinoma, many authors have reported that leucovorin (LV)-5FU therapy is effective in clinical studies (8)(9)(10)(11)(12). However, there are three reports that CDDP-5FU therapy is effective for advanced colorectal carcinoma (13)(14)(15).…”

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

“…However, once a tumour has spread beyond the colonic wall, the prognosis is much poorer [1,2]. The most studied therapy for advanced CRC is the combined cytotoxic agents 5‐fluorouracil and levamisole which achieves only a 20–40% objective remission rate with only a marginal improvement in survival [3,4]. One strategy subject to much investigation has been the use of monoclonal antibodies (mabs) directed against CRC‐associated antigens [5].…”